| Income Statement | 2026-06-30 | 2026-03-31 | ||
|---|---|---|---|---|
| Research and development (including non-cash stock-based compensation expense of 0.9 million and 0.6 million for three months ended june 30, 2026 and 2025, respectively and 1.8 million and 1.1 million for six months ended june 30, 2026 and 2025 respectively) | 24,619 | 21,431 | ||
| General and administrative (including non-cash stock-based compensation expense of 36.0 million and 1.2 million for the three months ended june 30, 2026 and 2025, respectively and 37.6 million and 2.3 million for six months ended june 30, 2026 and 2025 respectively | 41,189 | 6,112 | ||
| Total operating expenses | 65,808 | 27,543 | ||
| Loss from operations | -65,808 | -27,543 | ||
| Interest income, net | 3,257 | 2,133 | ||
| Research and development tax credit | 236 | 567 | ||
| Other expense, net | 34 | 46 | ||
| Total other income, net | 3,459 | 2,654 | ||
| Loss before income taxes | -62,349 | -24,889 | ||
| Income tax provision | 251 | 519 | ||
| Net loss | -62,600 | -25,408 | ||
| Foreign currency translation adjustment | 18 | 15 | ||
| Unrealized (loss) gain on available-for-sale securities | -557 | -252 | ||
| Comprehensive loss | -63,139 | -25,645 | ||
| Basic EPS | -1.78 | -10.34 | ||
| Diluted EPS | -1.78 | -10.34 | ||
| Basic Average Shares | 35,236,214 | 2,456,766 | ||
| Diluted Average Shares | 35,236,214 | 2,456,766 | ||
Seaport Therapeutics, Inc. (SPTX)
Seaport Therapeutics, Inc. (SPTX)